On The Pen GLP-1 News Titelbild

On The Pen GLP-1 News

On The Pen GLP-1 News

Von: Dave Knapp GLP-1 Industry Insider
Jetzt kostenlos hören, ohne Abo

Über diesen Titel

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.


Dave Knapp GLP-1 Industry Insider
Hygiene & gesundes Leben
  • BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
    Apr 23 2026

    Major disruption hits the GLP-1 landscape as another large 503B compounding pharmacy halts production of semaglutide and tirzepatide. In this episode, we unpack what’s driving the FDA’s increased enforcement and why these shutdowns could signal a broader shift in the compounded medication market.

    Joined by Sabina Hemmi from glpwinner.com, we break down the key differences between 503A and 503B pharmacies, what these changes mean for supply and patient access, and why delays in prescriptions may be on the horizon. We also dive into the growing legal battles between pharma companies and telehealth providers and what that could mean for the future of affordable GLP-1 options.

    If you’re using or considering compounded GLP-1s, this episode covers what you need to know right now and what could be coming next.

    Mehr anzeigen Weniger anzeigen
    41 Min.
  • Retatrutide Could Change Everything… But Who Actually Gets It?
    Apr 21 2026

    ON THE PEN RESOURCES AND LINKS: HTTPS://WWW.OTPLINKS.COM


    What if the most powerful obesity drug ever created ends up being the one you can’t get?

    That’s the real conversation around retatrutide right now.

    In this video, I break down what Eli Lilly is doing behind the scenes, and why this isn’t just about whether retatrutide is better than tirzepatide. This is about strategy. This is about access. And this is about who gets left behind.

    We’re talking about:
    • The push to classify retatrutide as a biologic
    • Why that could mean pricing in the $7,000/month range
    • How LillyDirect is changing access to tirzepatide
    • The “two lane” system that could define obesity treatment going forward
    • And what this means for patients already struggling to stay on GLP-1 therapies

    If you’ve ever fought insurance, dealt with compounding disappearing, or felt like the system decides what you’re allowed to have… this one is for you.

    👇 Let’s talk about it
    Have you ever felt stuck between “this is working” and “this isn’t enough”… with no clear path forward?



    Mehr anzeigen Weniger anzeigen
    30 Min.
  • Ozempic Personality With Dr Spencer Nadolsky
    Apr 19 2026

    This conversation dives headfirst into one of the most controversial and least understood side effects of GLP-1 medications, what many are now calling the “Ozempic personality.” In this candid interview, Dr. Spencer Nadolsky joins On The Pen to unpack the growing reports of anhedonia, a flattening of motivation, desire, and emotional highs that some patients experience, especially at higher doses of tirzepatide and similar therapies.


    What starts as a discussion about how these medications work in the brain quickly turns into something much deeper. We explore how GLP-1 and GIP receptor agonists don’t just reduce hunger, they fundamentally alter the brain’s reward system, dampening cravings, food noise, and in some cases, the very drive to seek pleasure at all. That is where the idea of the “Ozempic personality” begins to take shape, not as a diagnosis, but as a shared patient experience that is only now being taken seriously.


    Dave opens up about his own journey, spending years at the highest dose and slowly realizing that while the medication gave him control over food and blood sugar, it also quietly muted parts of his identity. Hobbies faded. Motivation shifted. The highs and lows of life became more… flat. And it wasn’t until stepping away that he could see the contrast clearly.


    Dr. Nadolsky brings clinical perspective to match the lived experience, explaining how this isn’t classic depression, but something more nuanced. Patients aren’t necessarily sad, they just stop wanting things. He shares how often this shows up in his practice, how he identifies it, and most importantly, how adjusting dose rather than stopping treatment altogether can restore balance.


    The conversation also raises bigger questions about transparency in clinical trials, what drug companies knew about these “anti-hedonic” effects, and why something so impactful may not have been formally tracked. At the same time, both Dave and Dr. Nadolsky emphasize what matters most, these medications are still life changing, even life saving, but they are not one size fits all.


    If you’ve ever felt like something changed beyond just your appetite while on a GLP-1, this is the conversation you’ve been waiting for. It puts language to an experience thousands are having but struggling to explain, and it gives you something even more important, a path forward.


    Watch the full interview to understand the reality behind the “Ozempic personality,” how to recognize it, and how to work with your doctor to find your own sweet spot.

    Mehr anzeigen Weniger anzeigen
    42 Min.
Noch keine Rezensionen vorhanden